Treatment Action Group releases an updated version of its Activist’s Guide to the LAM Test with a complementary resource that tracks the status of LAM uptake in the 30 high TB/HIV burden countries.

Treatment Action Group, Médecins Sans Frontières and Health GAP conducted a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

Treatment Action Group (TAG) and AVAC will host a webinar on 6 February 2020 featuring an update on recent vaccine results and possible next steps with M72/AS01E, one of several new TB vaccine candidates.

Activists urge Sanofi to do the same in other countries.

Treatment Action Group, Médecins Sans Frontières and Health GAP will host a webinar on 22 January 2020 on how to engage in PEPFAR Country Operational Plans (COPs) advocacy and promote the prioritization of interventions that address HIV co-infections and AIDS.

The report — Tuberculosis Research Funding Trends, 2005–2018 — presents new data on funding for TB research and development in 2018 and analyzes trends in spending since 2005.

Civil society takes legal action to contest patent applications filed by Sanofi on fixed-dose combinations of two decades-old drugs used to prevent TB.

The sections provide an overview of TB diagnostics, vaccines and treatment.

Quantification of investments in the development of bedaquiline finds total public and philanthropic expenditures are three to five times those of Johnson & Johnson.

The high cost of GeneXpert tests for TB leaves open a critical gap in the diagnosis of TB and fails to consider volume of sales and public investments in the development of GeneXpert.